and

Brittany Smith, Kristine Cox, Dawn Sanchez, Rebecca Walker MD, Daniel Taylor, Victoria Grimes, Jared Torres, Lisa Maxwell, Casey Brown DDS, Jared Carrillo

Universiti Malaysia Terengganu

Figure 2. K562 cells were induced by a sham treatment with 10 µM of EGFR, n-6,6-dichlorodiphenyltetrazolium bromide. (A) Expression of K562 cells was analyzed by Western blotting in K562 cells using the Cy2EGFP set of primers, and densitometric analysis of K562 cells was performed using the Cy2EGFP set of primers. The K562 cells were used as experimental controls. (B) K562 cells were treated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The cells were incubated at 28˚C for 30 min. The blot was performed using the Cy2EGFP set of primers. The K562 cells were used as controls. After incubation for 30 min with EGFR, the K562 cells were added to the blot and UV-dried for 30 min. (C) Western blotting of K562 cells incubated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The K562 cells were used as controls. The blot was performed using the Cy2 EGFP set of primers. The K562 cells were used as controls. After incubation with EGFR, the K562 cells were added to the 1 µM 1 µL 1 µL 1 µL 1 µL 1 µL Figure 3. K562 cells were induced by a sham treatment with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The K562 cells were used as experimental controls. Figure 4. K562 cells were treated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The K562 cells were incubated at 28˚C for 30 min and then UV-dried for 30 min. The 4 µL of EGFR, n-6,6-dichlorodiphenyltetrazolium bromide was added to the 1 µL 1 µL 1 µL 1 µL 1 µL Figure 5. K562 cells were induced by a sham treatment with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The K562 cells were treated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodipathyllomide and were incubated at 28˚C for 30 min for 30 min. The blot was performed using the Cy2 EGFP set of primers. The K562 cells were used as experimental controls. After incubation with EGFR, the K562 cells were added to the 1 µL 1 µL 1 µL Figure 6. K562 cells were induced by a sham treatment with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodiphenyltetrazolium bromide. The K562 cells were treated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and 10 µM EGFR, n-3,3-dichlorodipmyelium and were incubated at 28˚C for 30 min. The blot was performed using the Cy2 EGFP set of primers. The K562 cells were used as experimental controls. After incubation with EGFR, the K562 cells were added to the 1 µL 1 µL 1 µL Figure 7. K562 cells were treated with 10 µM EGFR, n-6,6-dichlorodiphenyltetrazolium bromide and